Vaccines based on messenger RNA technology have been tremendously successful, but their properties are not necessarily ideal for all pathogens. There is a risk that concentration on that technology alone for new vaccine development will ignore older technologies that have properties giving broader and more persistent protection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciae460 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Respiratory delivered vaccines: Current status and perspectives in rational formulation design.
Acta Pharm Sin B
December 2024
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
The respiratory tract is susceptible to various infections and can be affected by many serious diseases. Vaccination is one of the most promising ways that prevent infectious diseases and treatment of some diseases such as malignancy. Direct delivery of vaccines to the respiratory tract could mimic the natural process of infection and shorten the delivery path, therefore unique mucosal immunity at the first line might be induced and the efficiency of delivery can be high.
View Article and Find Full Text PDFDisparities in response to mRNA SARS-CoV-2 vaccines according to sex and age: A systematic review.
New Microbes New Infect
February 2025
Department of Global and Public Health, Epidemiology, Biostatistics and Prevention Institute, WHO Collaborating Centre for Travellers' Health, Centre of Competence for Military Medicine Biology, University of Zürich, Switzerland.
Background: The rapid development and distribution of mRNA COVID-19 vaccines has been essential in containing the SARS-CoV-2 epidemic around the globe. For ongoing and future immunization campaigns globally, there is a need to evaluate the impact of population demographics such as age and sex, on vaccine efficacy and safety.
Methods: This systematic review (PROSPERO ID CRD42023328245) conducted according to PRISMA guidelines evaluates the impact of age and sex on the safety and efficacy of the mRNA COVID-19 vaccinations administrated in 15 studies that were chosen according to strict criteria.
[Effectively preventing pneumococcal diseases in the elderly and the young].
Zhonghua Yi Xue Za Zhi
January 2025
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing102206, China.
Pneumococcal disease (PD) caused by (Sp) is a global public health concern. Children younger than 5 years and elderly over 60 years, due to immature development of the immune system early in life or the gradual decline of immune function with age, are high-risk groups for pneumococcal infections, which makes the disease burden particularly serious and the situation of prevention and control grim. Vaccination is the most effective measure to prevent PD and reduce pneumococcal antimicrobial resistance.
View Article and Find Full Text PDF[Optimize surveillance, prevention and control, vaccine strategies to respond to seasonal epidemics of respiratory infectious diseases].
Zhonghua Yi Xue Za Zhi
January 2025
Public Health Emergency Management Innovation Center, Key Laboratory of Pathogen Infection Prevention and Control (Peking Union Medical College), Ministry of Education, State Key Laboratory of Respiratory Health and Multimorbidity, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100730, China.
The prevalence and evolution of respiratory pathogens are changing, and issues related to drug-resistance are becoming increasingly prominent in the post-COVID era. The urgency of controlling respiratory pathogens has intensified. This issue organizes expert discussions to address the resurgence of various respiratory pathogens, summarizing current status of pathogen surveillance, drug-resistance research and vaccine development, while suggesting countermeasures.
View Article and Find Full Text PDFCohort profile: the potentially preventable burden of community-acquired pneumonia in South African adults in the era of widespread PCV13 immunisation and antiretroviral therapy roll-out, before and during the COVID-19 pandemic - the multicentre, multimethod PotPrev Study.
BMJ Open
December 2024
Perinatal HIV Research Unit (PHRU), University of the Witwatersrand Johannesburg, Johannesburg, Gauteng, South Africa.
Purpose: In the setting of an established childhood pneumococcal vaccination programme with immediate initiation and treatment of antiretroviral therapy (ART) for people living with HIV (PLWH), the risk of adult pneumococcal community-acquired pneumonia (CAP) is not recently described. We aimed to investigate CAP incidence, recurrence, mortality, risk factors and microbiology before and during the COVID-19 pandemic.
Participants: Adults aged ≥18 years were enrolled in three South African provinces from March 2019 to October 2021, with a brief halt during the initial COVID-19 lockdown.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!